Suramin treatment suppresses induction of experimental autoimmune uveoretinitis (EAU) in rodents
- 1 January 1995
- journal article
- research article
- Published by Taylor & Francis in Current Eye Research
- Vol. 14 (10) , 887-896
- https://doi.org/10.3109/02713689508995128
Abstract
The experimental drug suramin has been shown to possess several immunosuppressive properties. In this study we investigated the effect of suramin on the development of experimental autoimmune uveoretinitis (EAU) in mice and in rats. EAU was induced either by active immunization with a uveitogenic protein or peptide, or by the adoptive transfer of a uveitogenic T cell line. The development of EAU was assessed by clinical evaluation as well as by histopathology. Immunological responses were measured by delayed type hypersensitivity (DTH), lymphocyte proliferation, and serum antibody levels to the immunizing antigen. Suramin treatment was most effective in suppressing EAU when started concurrently with immunization (afferent). Treatment was less effective in suppressing disease when first administered 7 days after immunization or when given to animals that received an adoptive transfer of uveitogenic T cells (efferent). The effect of suramin on DTH and lymphocyte proliferation roughly paralleled its effect on EAU. Aferent treatment of mice with suramin completely suppressed anti-IRBP antibody titers. Interestingly, animals receiving efferent treatment had unreduced IgM levels but little or no IgG, suggesting prevention of the IgM-to-IgG switch. Depressed in vitro lymphocyte proliferative responses in animals treated with suramin during the afferent stage suggested that the suppressive effect on disease was due at least in part to an inhibition of antigen priming. Our results suggest that suramin merits further investigation as a potential treatment for some types of uveitis.Keywords
This publication has 25 references indexed in Scilit:
- Regulation of the interaction between Th1 and Th2 T cell clones to provide help for antibody productionin vivoEuropean Journal of Immunology, 1995
- Suramin blocks the binding of interleukin-1 to its receptor and neutralizes IL-1 biological activitiesInternational Journal of Immunopharmacology, 1994
- Uveitogenic T lymphocytes in the rat: pathogenicity vs. lymphokine production, adhesion molecules and surface antigen expressionJournal of Neuroimmunology, 1994
- Suramin interferes with interleukin-6 receptor binding in vitro and inhibits colon-26-mediated experimental cancer cachexia in vivo.Journal of Clinical Investigation, 1993
- Suramin Affects Human Peripheral Blood Mononuclear Cells in vitro: Inhibition of T Cell Growth and Modulation of Cytokine SecretionInternational Archives of Allergy and Immunology, 1993
- Induction of antibody synthesis by CD4+ T cells: IL 5 is essential for induction of antigen-specific antibody responses by TH2 but not TH1 clonesEuropean Journal of Immunology, 1990
- Suramin Blockade of Insulinlike Growth Factor I-Stimulated Proliferation of Human Osteosarcoma CellsJNCI Journal of the National Cancer Institute, 1990
- The mouse as a model of experimental autoimmune uveoretinitis (EAU)Current Eye Research, 1990
- Suppression of the development of experimental allergic encephalomyelitis by suraminNeuropharmacology, 1985
- Isolation and characterization of monkey interphotoreceptor retinoid-binding protein, a unique extracellular matrix component of the retinaBiochemistry, 1985